![Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/88c33a30-1781-4baa-9eae-b673fc22034a/gr1_lrg.jpg)
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
![Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD, - ppt download Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD, - ppt download](https://slideplayer.com/15456539/93/images/slide_1.jpg)
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD, - ppt download
![Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib - Journal of Thoracic Oncology Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/22484f10-b75d-4fac-9e9f-acf0500bfd54/gr1_lrg.jpg)
Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib - Journal of Thoracic Oncology
![Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/programs/nsclc-metex14/module-thumbs/cco-metex14-asco-cf_thumb11.png?rev=2592d5f249184e3c836951881e62602a)
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
![Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/4478dc7e-52d0-443d-a609-959490c0590d/gr1.jpg)
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
![Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2088033291/2074826410/gr1.jpg)
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
![MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/Fig-1-1.jpg)
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737220300608-gr3.jpg)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
![The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737220300608-gr4.jpg)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
![Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment - Journal of Thoracic Oncology Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/90b374e1-00e5-4705-9c10-ce9aa7728737/gr1_lrg.jpg)
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment - Journal of Thoracic Oncology
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation | JCO Precision Oncology
![References in Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer References in Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/df0dbf25-b023-4553-9f6b-87905379ae01/gr1.jpg)
References in Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
![A) Kaplan–Meier survival curves for relapse free according to MET exon... | Download Scientific Diagram A) Kaplan–Meier survival curves for relapse free according to MET exon... | Download Scientific Diagram](https://www.researchgate.net/publication/303540507/figure/fig2/AS:381336813621248@1467929189215/A-Kaplan-Meier-survival-curves-for-relapse-free-according-to-MET-exon-14-skipping-or.png)
A) Kaplan–Meier survival curves for relapse free according to MET exon... | Download Scientific Diagram
![Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram](https://www.researchgate.net/profile/Jeremy-Stinson/publication/7374944/figure/fig2/AS:667651978309640@1536192044800/Identification-of-tumor-specific-intronic-mutations-in-Met-leading-to-exon-14-splicing.png)
Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram
![METex14 in non-small lung cancers. (a) schematic diagram of genomic... | Download Scientific Diagram METex14 in non-small lung cancers. (a) schematic diagram of genomic... | Download Scientific Diagram](https://www.researchgate.net/publication/349331745/figure/fig1/AS:996950522486790@1614702935663/METex14-in-non-small-lung-cancers-a-schematic-diagram-of-genomic-areas-flanking-MET.png)
METex14 in non-small lung cancers. (a) schematic diagram of genomic... | Download Scientific Diagram
![The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016950021630527X-gr2.jpg)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
![Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. | Semantic Scholar Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/18b8f54c4d1d129c80a62b153dd2424d08095f04/2-Figure1-1.png)
Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. | Semantic Scholar
![Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping - Journal of Thoracic Oncology Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d0d8da51-5b1a-41eb-a0b5-81836f6b532f/gr1.jpg)
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping - Journal of Thoracic Oncology
![Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib](https://www.jcancer.org/v12/p0644/jcav12p0644g004.jpg)
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib
![A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/5/articles/49717/public/49717-PB5-3767-R1.png/w300)
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
![Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - Journal of Thoracic Oncology Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8d964320-0f80-4c1b-910f-3757da96ebde/gr2.jpg)